Thoracic Aortic Aneurysm Clinical Trial
— MOTAAROfficial title:
Predicting Moderate Thoracic Aortic Aneurysm Evolution: a Longitudinal Study of Systemic Factors in Patients Free of Connective Tissue Disease. .
Thoracic aneurysm is a silent disease with a potential mid-term high risk of death or major complications. Few data are available on the real incidence of major complications in case of small and moderate thoracic aneurysm. Different factors are supposed to increase the risk of aortic enlargement as high blood pressure and sleep disorder breathing. The modality of imaging and clinical follow-up are well defined. In this prospective observational study, the aim to assess the incidence of of major complications during follow-up in a population of patients with a small or moderate thoracic aneurysm. The study will also try to identify systemic factors influencing aneurysm evolution.
Status | Not yet recruiting |
Enrollment | 320 |
Est. completion date | October 2029 |
Est. primary completion date | October 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years to 80 Years |
Eligibility | Inclusion Criteria: - Documentation of an aortic root aneurysm > 40 mm - Agreement to participate to a longitudinal study and available for a 5 years follow-up Exclusion Criteria: - Presence of comorbidities or pathology with a prognosis of less than 1 year - Personal or family history of genetically documented elastic tissue disease or patient meeting the GAND clinical criteria suggestive of Marfan disease - High-grade mitra-aortic valve disease, even if asymptomatic - Unbalanced hypertension = 180/110 mmHg - Aneurysm (regardless of thoracic or abdominal location) = 50 mm - Aneurysm (regardless of thoracic or abdominal location) with documented progression of more than 5 mm over one year - History of aortic surgery or endovascular intervention and history of type B aortic dissection of medical treatment - Renal insufficiency on dialysis, or GFR< 30 ml/mn (CKD-EPI) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille | Association de Cardiologie Nord-Pas de Calais, Région Nord-Pas de Calais, France, Santelys Association |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence within 5 years of inclusion of a major aortic even | This composite end point is defined as the occurrence of:
Aneurysm-related death Emergency surgery for threatened aortic rupture or aortic dissection Scheduled surgery for aneurysmal dilatation of more than 5 mm over 1 year Aneurysm progression exceeding 55 mm in diameter Root surgery for management of symptomatic aortic valve disease (insufficiency or narrowing) of high grade defined by tight aortic narrowing (V Max=4 m/s, mean gradient =40mmHg, and area =1cm² or severe aortic insufficiency (regurgitated volume=60 ml, shortening fraction= 50%. |
during the 5 years after inclusion | |
Secondary | Number of Participants with controlled blood pressure defined by ambulatory blood pressure measurement | The blood pressure measurement (averaged over 24 h)<130/80 mmHg and nocturnal blood pressure =120/70 mmHg | during the 2 years after inclusion | |
Secondary | Presence of sleep disorders defined by an 'Apnea Hypopnea Index and/or an Oxygen Desaturation Index | for Apnea Hypopnea Index = =5 events per hour for Oxygen Desaturation Index = =5 events per hour | during the 2 years after inclusion | |
Secondary | Occurrence during the 5 years after inclusion of a major cardiovascular event | This composite criterion is defined by the occurrence of death from cardiovascular causes, myocardial infarction, stroke (ischemic or hemorrhagic), or hospitalization for heart failure | during the 5 years after inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01390181 -
The Effect of Losartan in Bicuspid Aortic Valve Patients
|
N/A | |
Recruiting |
NCT00339053 -
Immunonutrition and Thoracoabdominal Aorta Aneurysm Repair
|
Phase 4 | |
Recruiting |
NCT00549315 -
Clinical Study of Thoracic Aortic Aneurysm Exclusion
|
N/A | |
Recruiting |
NCT05777460 -
Mid- and Long-term Outcomes of Custom-made Aortic Devices
|
||
Active, not recruiting |
NCT05146375 -
Genes Modulating the Severity of Aortic Aneurysms (MSF1-TGFBR2)
|
||
Completed |
NCT01082172 -
South American Thoracic Stent-Graft Study
|
N/A | |
Recruiting |
NCT03824626 -
Biomechanical Reappraisal of Planning for Thoracic Endovascular Aortic Repair
|
||
Completed |
NCT04663074 -
Intravascular Ultrasound (IVUS) in Complex Aortic Endovascular Interventions
|
||
Recruiting |
NCT04747626 -
B-SAFER: Branched Stented Anastomosis Frozen Elephant Trunk Repair
|
N/A | |
Active, not recruiting |
NCT05143138 -
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used as a Bridging Stent With Branched and Fenestrated Endografts in the Treatment of Aortic Aneurysms Involving the Renal-Mesenteric Arteries
|
||
Completed |
NCT00111176 -
STARZ-TX2 Clinical Study: Study of Thoracic Aortic Aneurysm Repair With the Zenith TX2 Endovascular Graft
|
N/A | |
Recruiting |
NCT05639400 -
Thoraflex Hybrid and Relay Extension Post-Approval Study
|
||
Terminated |
NCT02735720 -
The CardiOvascular Remodeling Following Endovascular Aortic Repair (CORE) Study
|
||
Completed |
NCT02256163 -
Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm
|
N/A | |
Recruiting |
NCT06377033 -
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
|
N/A | |
Recruiting |
NCT06094127 -
Zenith Thoracic Alpha (ZTA) Post-Market Data Collection
|
||
Recruiting |
NCT03998631 -
Comparison of Carbon Dioxide and Saline Flush to Saline Flush in TEVAR and TAVI Procedures to Reduce Cerebral Ischemia
|
Phase 1 | |
Completed |
NCT05414318 -
CTAG Dissection/Trauma Post Marketing Surveillance Japan
|
||
Completed |
NCT04756778 -
Indexed Aortic Area in Bicuspid Aortic Valve Aortopathy
|
||
Withdrawn |
NCT04197648 -
Effects of Exercise on Thoracic Aneurysms
|
N/A |